ClinicalTrials.gg
TerminatedNCT06161116Updated Aug 10, 2026Results posted

Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

A Phase 2 interventional study of MK-6194 and Placebo in Systemic Lupus Erythematosus, sponsored by Merck Sharp & Dohme LLC. Terminated at 127 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Why this study was terminated
Business Reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Enrollment
57th of 245
149 · median 36
Started
2023
with 23 others
Phase 2
33 of 266
14 open now
Registered
104th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 57th largest by enrollment of the 245 interventional ones that give a count, is one of 24 that started in 2023, is one of 33 in phase 2, and was the 104th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with systemic lupus erythematosus.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a diagnosis of systemic lupus erythematosus (SLE) ≥6 months prior to Screening.
  • Is taking at least 1 background therapy (1 or dapsone and/or 1 antimalarial and/or oral ) for SLE.
  • Has positive antinuclear antibody (+ANA; titer ≥1:80) or positive anti-double-strand deoxyribonucleic acid (dsDNA) antibody or positive anti-Smith (anti-Sm) antibody, or positive anti-Sjögren's Syndrome A (SSA)/Ro antibody.
  • Has the presence of at least 1 of the following manifestations of SLE: active lupus rash with Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) erythema and scale/hypertrophy combined score >2, or >2 tender and swollen joints in wrists, metacarpophalangeals (MCPs), or proximal interphalangeals (PIPs).
  • Has a hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score of ≥6 and clinical hybrid SLEDAI score of ≥4.

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a concurrent disease or clinically relevant laboratory abnormalities, or a history of any illness or medical condition that might confound the results of the study or poses an additional risk to the participant by their participation in the study.
  • Has symptomatic heart failure ( Class III or IV) or myocardial infarction or unstable angina pectoris within 6 months prior to Screening.
  • Has a severe chronic pulmonary disease requiring oxygen therapy.
  • Has a transplanted organ which requires continued .
  • Has a known systemic to interleukin-2 (IL-2), or modified IL-2 including MK-6194, or its inactive ingredients.
  • Has a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
  • Has drug-induced cutaneous lupus erythematosus (CLE) and/or drug-induced SLE in the setting of continued treatment with a causative agent.
  • Has active or unstable neuropsychiatric lupus including but not limited to the following: seizure, new or worsening impaired level of consciousness, psychosis, delirium or confused state, aseptic meningitis, cranial neuropathy, cerebrovascular accident, ascending or transverse myelitis, chorea, cerebellar ataxia, mononeuritis multiplex, or demyelinating syndromes.
  • Has a diagnosis of antiphospholipid syndrome (APS) with history of vascular thrombosis, catastrophic APS, or pregnancy morbidity within 6 months prior to Screening.
  • Has a history of any , except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix.
  • Has an active or clinically significant infection requiring hospitalization or treatment with anti-infectives.
  • Has evidence of active tuberculosis (TB), latent TB, or inadequately treated TB.
  • Has confirmed or suspected coronavirus disease of 2019 (COVID-19) infection.
  • Has had major surgery within 3 months prior to Screening or has a major surgery planned during the study.
  • Is taking more than 1 immunosuppressant.
  • Is taking more than 1 oral nonsteroidal anti-inflammatory drug (NSAID), excluding low-dose aspirin (\<350 mg/day), or is taking daily oral NSAID at greater than the maximum recommended dosage.
  • Is currently on any chronic systemic (oral or intravenous [IV]) anti-infective therapy for chronic active infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    MK-6194 3 mg Q2W

    Participants receive subcutaneous (SC) MK-6194 3 mg every 2 weeks (q2w).

    Biological: MK-6194

  • Experimental
    MK-6194 3 mg Q4W

    Participants receive SC MK-6194 3 mg every 4 weeks (q4w).

    Biological: MK-6194

  • Placebo comparator
    Placebo

    Participants receive SC placebo q2w.

    Biological: Placebo

  • Experimental
    MK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period)

    After completing 52 weeks of treatment with SC MK-6194 administered 3 mg q2w in the main study, participants continue to receive SC MK-6194 3 mg q2w in the extension period.

    Biological: MK-6194

  • Experimental
    MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period)

    After completing 52 weeks of treatment with SC MK-6194 administered 3 mg q4w in the main study, participants continue to receive SC MK-6194 3 mg q4w in the extension period.

    Biological: MK-6194

  • Experimental
    Placebo (Main Study)/ MK-6194 3 mg Q2W (Extension Period)

    After completing 52 weeks of treatment with SC placebo administered q2w in the main study, participants are re-randomized to receive SC MK-6194 3 mg q2w in the extension period.

    Biological: MK-6194 · Biological: Placebo

  • Experimental
    Placebo (Main Study)/ MK-6194 3 mg Q4W (Extension Period)

    After completing 52 weeks of treatment with SC placebo administered q2w in the main study, participants are re-randomized to receive SC MK-6194 3 mg q4w in the extension period.

    Biological: MK-6194 · Biological: Placebo

Interventions

  • BiologicalMK-6194

    SC Injection

  • BiologicalPlacebo

    SC Injection

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Systemic Lupus Erythematosus Responder Index (SRI-4) Response at Week 28

    The SRI was a composite index used to assess clinical improvement in participants with SLE. The SRI-4 response evaluated global improvement, any significant worsening in unaffected organ systems, and improvements in disease activity, without compromise to the participant's overall condition. SRI-4 response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

    Time frame: Week 28

  2. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs were reported based on study treatment received by the participant at time of event. The number of participants who experienced one or more AEs was reported.

    Time frame: Up to approximately 16 months

  3. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs were reported based on study treatment received by the participant at time of event. The number of participants who discontinued study treatment due to an AE was reported.

    Time frame: Up to approximately 16 months

Secondary outcomes

  1. Number of Participants Achieving British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) Response at Week 28

    The BICLA response was a composite global measure of SLE disease activity. It distinguished between partial and complete improvement in all body systems. BICLA response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

    Time frame: Week 28

  2. Number of Participants Achieving SRI-4 Response at Week 52

    The SRI was a composite index used to assess clinical improvement in participants with SLE. The SRI-4 response evaluated global improvement, any significant worsening in unaffected organ systems, and improvements in disease activity, without compromise to the participant's overall condition. SRI-4 response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

    Time frame: Week 52

  3. Number of Participants Achieving BICLA Response at Week 52

    The BICLA response was a composite global measure of SLE disease activity. It distinguished between partial and complete improvement in all body systems. BICLA response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

    Time frame: Week 52

  4. Number of Participants With a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-50 Response at Week 28

    The CLASI-A score was used to evaluate lupus skin manifestations, with higher scores indicating increased disease severity and lower scores indicating less disease severity. CLASI-A scores of 0 to 9, 10 to 20, and 21 to 70 represented disease severity of mild, moderate, and severe, respectively. CLASI-50 was 50% improvement from baseline in the CLASI-A score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

    Time frame: Week 28

  5. Number of Participants With a CLASI-50 Response at Week 52

    The CLASI-A score was used to evaluate lupus skin manifestations, with higher scores indicating increased disease severity and lower scores indicating less disease severity. CLASI-A scores of 0 to 9, 10 to 20, and 21 to 70 represented disease severity of mild, moderate, and severe, respectively. CLASI-50 was 50% improvement from baseline in the CLASI-A score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

    Time frame: Week 52

  6. Change From Baseline in Swollen Joint Count at Week 28

    The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.

    Time frame: Baseline and Week 28

  7. Change From Baseline in Swollen Joint Count at Week 52

    The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.

    Time frame: Baseline and Week 52

  8. Change From Baseline in Tender Joint Count at Week 28

    The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.

    Time frame: Baseline and Week 28

  9. Change From Baseline in Tender Joint Count at Week 52

    The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.

    Time frame: Baseline and Week 52

  10. Change From Baseline in Swollen and Tender Joint Count at Week 28

    The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling and presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.

    Time frame: Baseline and Week 28

  11. Change From Baseline in Swollen and Tender Joint Count at Week 52

    The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling and presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.

    Time frame: Baseline and Week 52

  12. Change From Baseline in Oral Corticosteroid Dose at Week 28

    Participants were assessed for corticosteroid dose change. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The oral corticosteroid dose at Week 28 was determined by the visit window of Week 28 (±7 days). Missing Week 28 dose was imputed with 0 if the participant completed Week 28 efficacy assessments. Oral corticosteroid doses as the weighted average of all doses taken at Week 28, weighted by the number of days each oral corticosteroid dose was administered was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.

    Time frame: Baseline and Week 28

  13. Change From Baseline in Oral Corticosteroid Dose at Week 52

    Participants were assessed for corticosteroid dose change. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The oral corticosteroid dose at Week 52 was determined by the visit window of Week 52 (±7 days). Missing Week 52 dose was imputed with 0 if the participant completed Week 52 efficacy assessments. Oral corticosteroid doses as the weighted average of all doses taken at Week 52, weighted by the number of days each oral corticosteroid dose was administered was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.

    Time frame: Baseline and Week 52

  14. Cumulative Oral Corticosteroid Use Between Week 0 and Week 28

    Participants were assessed for cumulative oral corticosteroid dose. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The cumulative oral corticosteroid dose at Week 28, calculated from Week 0 (Day 1) to Week 28 was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.

    Time frame: Up to approximately 28 weeks

  15. Cumulative Oral Corticosteroid Use Between Week 0 and Week 52

    Participants were assessed for cumulative oral corticosteroid dose. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The cumulative oral corticosteroid dose at Week 52, calculated from Week 0 (Day 1) to Week 52 was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.

    Time frame: Up to approximately 52 weeks

  16. Number of Participants Who Achieved Low Level of Disease Activity (LLDAS) at Week 28

    LLDAS was a low disease activity state associated with significant protection against flares and organ damage accrual. It included both the measurement of disease activity and maintenance of immunosuppressive medications. LLDAS response was defined as hybrid SLEDAI ≤4 (with no activity in major organ systems), no new features of SLE activity compared with previous assessment, physician's global assessment (PGA) ≤1.0, current prednisone (or equivalent) dose ≤7.5 mg daily, and well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs. LLDAS response was binary and was either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

    Time frame: Week 28

  17. Number of Participants Who Achieved LLDAS at Week 52

    LLDAS was a low disease activity state associated with significant protection against flares and organ damage accrual. It included both the measurement of disease activity and maintenance of immunosuppressive medications. LLDAS response was defined as hybrid SLEDAI ≤4 (with no activity in major organ systems), no new features of SLE activity compared with previous assessment, physician's global assessment (PGA) ≤1.0, current prednisone (or equivalent) dose ≤7.5 mg daily, and well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs. LLDAS response was binary and was either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

    Time frame: Week 52

07

Results

Posted Aug 10, 2026
Limitations and caveats
Due to early termination, the sample size was insufficient for comparative statistical analysis.

Participant flow

Main Study
Participant flow — Main Study
MilestoneMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboMK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period)MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period)Placebo (Main Study)/ MK-6194 3 mg Q2W (Extension Period)Placebo (Main Study)/ MK-6194 3 mg Q4W (Extension Period)
Started4949510000
Treated4949510000
Completed2460000
Not completed4745450000
Withdrew: Death0010000
Withdrew: Lost to follow-up1000000
Withdrew: Physician decision1310000
Withdrew: Study terminated by sponsor3939410000
Withdrew: Withdrawal by subject3120000
Withdrew: Other3200000
Extension Period
Participant flow — Extension Period
MilestoneMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboMK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period)MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period)Placebo (Main Study)/ MK-6194 3 mg Q2W (Extension Period)Placebo (Main Study)/ MK-6194 3 mg Q4W (Extension Period)
Started0002424
Treated0002424
Completed0000000
Not completed0002424
Withdrew: Study terminated by sponsor0002424

Outcome measures

SecondaryNumber of Participants Achieving British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) Response at Week 28

The BICLA response was a composite global measure of SLE disease activity. It distinguished between partial and complete improvement in all body systems. BICLA response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

Time frame:
Week 28
Reported as:
Count of participants · Participants
Number of Participants Achieving British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) Response at Week 28
ParticipantsMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Number of Participants Achieving British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) Response at Week 281266
SecondaryNumber of Participants Achieving SRI-4 Response at Week 52

The SRI was a composite index used to assess clinical improvement in participants with SLE. The SRI-4 response evaluated global improvement, any significant worsening in unaffected organ systems, and improvements in disease activity, without compromise to the participant's overall condition. SRI-4 response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants Achieving SRI-4 Response at Week 52
ParticipantsMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Number of Participants Achieving SRI-4 Response at Week 52344
SecondaryNumber of Participants Achieving BICLA Response at Week 52

The BICLA response was a composite global measure of SLE disease activity. It distinguished between partial and complete improvement in all body systems. BICLA response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants Achieving BICLA Response at Week 52
ParticipantsMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Number of Participants Achieving BICLA Response at Week 52324
SecondaryNumber of Participants With a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-50 Response at Week 28

The CLASI-A score was used to evaluate lupus skin manifestations, with higher scores indicating increased disease severity and lower scores indicating less disease severity. CLASI-A scores of 0 to 9, 10 to 20, and 21 to 70 represented disease severity of mild, moderate, and severe, respectively. CLASI-50 was 50% improvement from baseline in the CLASI-A score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

Time frame:
Week 28
Reported as:
Count of participants · Participants
Number of Participants With a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-50 Response at Week 28
ParticipantsMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Number of Participants With a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-50 Response at Week 28420
SecondaryNumber of Participants With a CLASI-50 Response at Week 52

The CLASI-A score was used to evaluate lupus skin manifestations, with higher scores indicating increased disease severity and lower scores indicating less disease severity. CLASI-A scores of 0 to 9, 10 to 20, and 21 to 70 represented disease severity of mild, moderate, and severe, respectively. CLASI-50 was 50% improvement from baseline in the CLASI-A score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants With a CLASI-50 Response at Week 52
ParticipantsMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Number of Participants With a CLASI-50 Response at Week 52210
SecondaryChange From Baseline in Swollen Joint Count at Week 28

The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.

Time frame:
Baseline and Week 28
Reported as:
Mean · Score on a scale
Change From Baseline in Swollen Joint Count at Week 28
Score on a scaleMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Change From Baseline in Swollen Joint Count at Week 28-6.9 ± 5.1-7.4 ± 4.6-5.6 ± 5.0
SecondaryChange From Baseline in Swollen Joint Count at Week 52

The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.

Time frame:
Baseline and Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in Swollen Joint Count at Week 52
Score on a scaleMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Change From Baseline in Swollen Joint Count at Week 521.3 ± 11.3-6.2 ± 3.3-5.9 ± 3.8
SecondaryChange From Baseline in Tender Joint Count at Week 28

The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.

Time frame:
Baseline and Week 28
Reported as:
Mean · Score on a scale
Change From Baseline in Tender Joint Count at Week 28
Score on a scaleMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Change From Baseline in Tender Joint Count at Week 28-10.8 ± 7.9-10.2 ± 6.7-9.4 ± 6.7
SecondaryChange From Baseline in Tender Joint Count at Week 52

The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.

Time frame:
Baseline and Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in Tender Joint Count at Week 52
Score on a scaleMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Change From Baseline in Tender Joint Count at Week 52-1.8 ± 7.9-7.0 ± 3.8-9.6 ± 6.7
SecondaryChange From Baseline in Swollen and Tender Joint Count at Week 28

The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling and presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.

Time frame:
Baseline and Week 28
Reported as:
Mean · Score on a scale
Change From Baseline in Swollen and Tender Joint Count at Week 28
Score on a scaleMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Change From Baseline in Swollen and Tender Joint Count at Week 28-6.9 ± 5.2-7.4 ± 4.6-5.6 ± 5.0
SecondaryChange From Baseline in Swollen and Tender Joint Count at Week 52

The joint count score was an evaluation of 28 joints in which joints were assessed for presence or absence of swelling and presence or absence of tenderness. The number of affected joints could have ranged from 0 to 28; with higher values corresponding to higher disease activity and lower values to less disease activity. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations was reported.

Time frame:
Baseline and Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in Swollen and Tender Joint Count at Week 52
Score on a scaleMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Change From Baseline in Swollen and Tender Joint Count at Week 521.3 ± 11.3-6.6 ± 3.6-5.9 ± 3.8
SecondaryChange From Baseline in Oral Corticosteroid Dose at Week 28

Participants were assessed for corticosteroid dose change. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The oral corticosteroid dose at Week 28 was determined by the visit window of Week 28 (±7 days). Missing Week 28 dose was imputed with 0 if the participant completed Week 28 efficacy assessments. Oral corticosteroid doses as the weighted average of all doses taken at Week 28, weighted by the number of days each oral corticosteroid dose was administered was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.

Time frame:
Baseline and Week 28
Reported as:
Mean · mg
Change From Baseline in Oral Corticosteroid Dose at Week 28
mgMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Change From Baseline in Oral Corticosteroid Dose at Week 28-3.5 ± 7.4-5.2 ± 5.0-4.2 ± 5.9
SecondaryChange From Baseline in Oral Corticosteroid Dose at Week 52

Participants were assessed for corticosteroid dose change. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The oral corticosteroid dose at Week 52 was determined by the visit window of Week 52 (±7 days). Missing Week 52 dose was imputed with 0 if the participant completed Week 52 efficacy assessments. Oral corticosteroid doses as the weighted average of all doses taken at Week 52, weighted by the number of days each oral corticosteroid dose was administered was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.

Time frame:
Baseline and Week 52
Reported as:
Mean · mg
Change From Baseline in Oral Corticosteroid Dose at Week 52
mgMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Change From Baseline in Oral Corticosteroid Dose at Week 52-5.5 ± 2.7-8.5 ± 7.4-8.3 ± 4.9
SecondaryCumulative Oral Corticosteroid Use Between Week 0 and Week 28

Participants were assessed for cumulative oral corticosteroid dose. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The cumulative oral corticosteroid dose at Week 28, calculated from Week 0 (Day 1) to Week 28 was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.

Time frame:
Up to approximately 28 weeks
Reported as:
Mean · mg
Cumulative Oral Corticosteroid Use Between Week 0 and Week 28
mgMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Cumulative Oral Corticosteroid Use Between Week 0 and Week 281509.3 ± 947.41540.8 ± 758.31622.7 ± 822.0
SecondaryCumulative Oral Corticosteroid Use Between Week 0 and Week 52

Participants were assessed for cumulative oral corticosteroid dose. Oral corticosteroid dose was based on prednisone or prednisone-equivalent dose. The cumulative oral corticosteroid dose at Week 52, calculated from Week 0 (Day 1) to Week 52 was reported. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of means and standard deviations were reported.

Time frame:
Up to approximately 52 weeks
Reported as:
Mean · mg
Cumulative Oral Corticosteroid Use Between Week 0 and Week 52
mgMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Cumulative Oral Corticosteroid Use Between Week 0 and Week 521355.6 ± 919.42268.1 ± 710.12047.5 ± 1089.3
SecondaryNumber of Participants Who Achieved Low Level of Disease Activity (LLDAS) at Week 28

LLDAS was a low disease activity state associated with significant protection against flares and organ damage accrual. It included both the measurement of disease activity and maintenance of immunosuppressive medications. LLDAS response was defined as hybrid SLEDAI ≤4 (with no activity in major organ systems), no new features of SLE activity compared with previous assessment, physician's global assessment (PGA) ≤1.0, current prednisone (or equivalent) dose ≤7.5 mg daily, and well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs. LLDAS response was binary and was either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

Time frame:
Week 28
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Low Level of Disease Activity (LLDAS) at Week 28
ParticipantsMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Number of Participants Who Achieved Low Level of Disease Activity (LLDAS) at Week 28422
PrimaryNumber of Participants Achieving Systemic Lupus Erythematosus Responder Index (SRI-4) Response at Week 28

The SRI was a composite index used to assess clinical improvement in participants with SLE. The SRI-4 response evaluated global improvement, any significant worsening in unaffected organ systems, and improvements in disease activity, without compromise to the participant's overall condition. SRI-4 response was binary and either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

Time frame:
Week 28
Reported as:
Count of participants · Participants
Number of Participants Achieving Systemic Lupus Erythematosus Responder Index (SRI-4) Response at Week 28
ParticipantsMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Number of Participants Achieving Systemic Lupus Erythematosus Responder Index (SRI-4) Response at Week 2815910
PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs were reported based on study treatment received by the participant at time of event. The number of participants who experienced one or more AEs was reported.

Time frame:
Up to approximately 16 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboMK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period)MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period)Placebo (Main Study)/ MK-6194 3 mg Q2W (Extension Period)Placebo (Main Study)/ MK-6194 3 mg Q4W (Extension Period)
Number of Participants Who Experienced an Adverse Event (AE)3838351101
PrimaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs were reported based on study treatment received by the participant at time of event. The number of participants who discontinued study treatment due to an AE was reported.

Time frame:
Up to approximately 16 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboMK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period)MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period)Placebo (Main Study)/ MK-6194 3 mg Q2W (Extension Period)Placebo (Main Study)/ MK-6194 3 mg Q4W (Extension Period)
Number of Participants Who Discontinued Study Treatment Due to an AE4610000
SecondaryNumber of Participants Who Achieved LLDAS at Week 52

LLDAS was a low disease activity state associated with significant protection against flares and organ damage accrual. It included both the measurement of disease activity and maintenance of immunosuppressive medications. LLDAS response was defined as hybrid SLEDAI ≤4 (with no activity in major organ systems), no new features of SLE activity compared with previous assessment, physician's global assessment (PGA) ≤1.0, current prednisone (or equivalent) dose ≤7.5 mg daily, and well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs. LLDAS response was binary and was either achieved or not achieved by the participant, thus there was no associated score. Due to insufficient sample size, no statistical analysis was performed. Descriptive statistics in the form of counts calculated as percentages was reported.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Achieved LLDAS at Week 52
ParticipantsMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlacebo
Number of Participants Who Achieved LLDAS at Week 52000

Adverse events

Collected over Up to approximately 19 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-6194 3 mg Q2W0/49 (0%)5/49 (10.2%)29/49 (59.2%)
MK-6194 3 mg Q4W0/49 (0%)5/49 (10.2%)25/49 (51%)
Placebo1/51 (2%)4/51 (7.8%)22/51 (43.1%)
MK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period)0/2 (0%)0/2 (0%)1/2 (50%)
MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period)0/4 (0%)0/4 (0%)1/4 (25%)
Placebo (Main Study) / MK-6194 3 mg Q2W (Extension Period)0/2 (0%)0/2 (0%)0/2 (0%)
Placebo (Main Study) / MK-6194 3 mg Q4W (Extension Period)0/4 (0%)1/4 (25%)1/4 (25%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboMK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period)MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period)Placebo (Main Study) / MK-6194 3 mg Q2W (Extension Period)Placebo (Main Study) / MK-6194 3 mg Q4W (Extension Period)
HydronephrosisRenal and urinary disorders0/490/490/510/20/40/21/4
AppendicitisInfections and infestations0/491/490/510/20/40/20/4
BacteraemiaInfections and infestations1/490/490/510/20/40/20/4
Gastroenteritis viralInfections and infestations1/490/490/510/20/40/20/4
Herpes zosterInfections and infestations1/491/490/510/20/40/20/4
PneumoniaInfections and infestations1/490/490/510/20/40/20/4
PyelonephritisInfections and infestations0/491/490/510/20/40/20/4
Respiratory tract infectionInfections and infestations0/491/490/510/20/40/20/4
Upper respiratory tract infectionInfections and infestations0/491/490/510/20/40/20/4
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders1/490/490/510/20/40/20/4
Most frequent other events
Showing 10 of 24
Most frequent other events
EventMK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboMK-6194 3 mg Q2W (Main Study) / MK-6194 3 mg Q2W (Extension Period)MK-6194 3 mg Q4W (Main Study) / MK-6194 3 mg Q4W (Extension Period)Placebo (Main Study) / MK-6194 3 mg Q2W (Extension Period)Placebo (Main Study) / MK-6194 3 mg Q4W (Extension Period)
Muscle strainInjury, poisoning and procedural complications0/490/490/511/20/40/20/4
FatigueGeneral disorders2/490/492/510/21/40/20/4
Injection site reactionGeneral disorders6/492/490/510/20/40/21/4
CoughRespiratory, thoracic and mediastinal disorders0/490/492/510/21/40/20/4
Upper respiratory tract infectionInfections and infestations8/495/492/510/20/40/20/4
HeadacheNervous system disorders3/496/498/510/20/40/20/4
Injection site erythemaGeneral disorders6/492/490/510/20/40/20/4
GastroenteritisInfections and infestations0/495/491/510/20/40/20/4
Urinary tract infectionInfections and infestations5/492/491/510/20/40/20/4
GastritisGastrointestinal disorders4/491/490/510/20/40/20/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
Mean40.9 ± 13.840.4 ± 12.041.2 ± 14.040.8 ± 13.2
Age, Customized
Age, Customized(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
Adults (Between 18 and 64 Years)484849145
From 65 to 84 Years1124
Sex: Female, Male
Sex: Female, Male(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
Female484645139
Male13610
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
Hispanic or Latino29252983
Not Hispanic or Latino20242266
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
American Indian or Alaska Native15101237
Asian8131536
Native Hawaiian or Other Pacific Islander1001
Black or African American4307
White20212061
More than one race1247
Unknown or Not Reported0000
Total Hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Score at Screening
Total Hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Score at Screening(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
<1027272983
≥1022222266
Oral Corticosteroid Dose (Prednisone or Equivalent) at Randomization
Oral Corticosteroid Dose (Prednisone or Equivalent) at Randomization(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
<10 mg/day26272780
≥10 mg/day23222469
Geographic Region
Geographic Region(Participants)MK-6194 3 mg Q2WMK-6194 3 mg Q4WPlaceboTotal
Latin America/Eastern Europe24242674
Rest of the World25252575
08

Study locations

127 sites
  • Medvin Clinical Research - Metyas ( Site 0128)
    Covina, California 91722, United States
  • UCSD - Altman Clinical and Translational Research Institute (ACTRI)-Center for Innovative Therapy ( Site 0110)
    La Jolla, California 92037, United States
  • Arthritis & Osteoporosis Medical Center - La Palma ( Site 0108)
    La Palma, California 90623, United States
  • Medvin Clinical Research - Tujunga ( Site 0127)
    Tujunga, California 91042, United States
  • Denver Arthritis Clinic ( Site 0102)
    Denver, Colorado 80230, United States
  • Clinical Research of West Florida, Inc. (Clearwater) ( Site 0111)
    Clearwater, Florida 33765, United States
  • IRIS Research and Development, LLC-Research ( Site 0117)
    Plantation, Florida 33324, United States
  • Clinical Research of West Florida, Inc ( Site 0124)
    Tampa, Florida 33606, United States
  • Morehouse School of Medicine ( Site 0146)
    Atlanta, Georgia 30310, United States
  • Accurate Clinical Research, Inc ( Site 0135)
    Lake Charles, Louisiana 70605, United States
  • AA Medical Research Center ( Site 0136)
    Grand Blanc, Michigan 48439, United States
  • Javara - Tryon Medical Partners ( Site 0121)
    Charlotte, North Carolina 28210, United States
  • DJL Clinical Research, PLLC ( Site 0103)
    Charlotte, North Carolina 28211, United States
  • University of Oklahoma Health Science Center ( Site 0130)
    Oklahoma City, Oklahoma 73104, United States
  • Shelby Research, LLC ( Site 0142)
    Memphis, Tennessee 38119, United States
  • Accurate Clinical Management, LLC. ( Site 0134)
    Baytown, Texas 77521, United States
  • Epic Medical Research ( Site 0113)
    DeSoto, Texas 75115, United States
  • Accurate Clinical Research, Inc. ( Site 0133)
    Houston, Texas 77089, United States
  • SouthWest Rheumatology Research, LLC ( Site 0115)
    Mesquite, Texas 75150, United States
  • Centro de Investigaciones Médicas Mar del Plata ( Site 0210)
    Mar del Plata, Buenos Aires 7600, Argentina
  • Sanatorio Parque ( Site 0205)
    Rosario, Santa Fe Province S2000DVC, Argentina
  • Clínica de Nefrología, Urología y Enfermedades Cardiovasculares ( Site 0206)
    Santa Fe, Santa Fe Province S3000BPJ, Argentina
  • Centro de Investigaciones Médicas Tucuman ( Site 0203)
    SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
  • Instituto de Reumatología ( Site 0201)
    Mendoza, M5500CPH, Argentina
  • IPC - MT Instituto de Pesquisas Clínicas do Mato Grosso ( Site 0313)
    Cuiabá, Mato Grosso 78020-500, Brazil
  • Núcleo de Pesquisa Clínica do Rio Grande do Sul ( Site 0309)
    Porto Alegre, Rio Grande do Sul 90430-001, Brazil
  • LMK Serviços Médicos S/S-Reumacenter ( Site 0303)
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
  • Centro Multidisciplinar de Estudos Clinicos ( Site 0302)
    São Bernardo do Campo, São Paulo 09715-090, Brazil
  • Hospital de Base de São José do Rio Preto-CIP - Centro Integrado de Pesquisas ( Site 0311)
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Diex Recherche Sherbrooke ( Site 0003)
    Sherbrooke, Quebec J1L 0H8, Canada
  • James Lind Centro de Investigacion del Cancer ( Site 0407)
    Temuco, Araucania 4800827, Chile
  • IC La Serena Research ( Site 0414)
    La Serena, Coquimbo Region 1720430, Chile
  • Clinica Dermacross ( Site 0416)
    Santiago, Region M. de Santiago 7640881, Chile
  • Complejo Asistencial Dr. Sotero del Rio ( Site 0402)
    Santiago, Region M. de Santiago 8207257, Chile
  • CECIM ( Site 0405)
    Santiago, Region M. de Santiago 8320000, Chile
  • Centro Internacional de Estudios Clinicos (CIEC) ( Site 0410)
    Santiago, Region M. de Santiago 8420383, Chile
  • The First Afflilated Hospital of Bengbu Medical College-Urology Surgery ( Site 2019)
    Bengbu, Anhui 233000, China
  • Anhui Provincial Hospital ( Site 2043)
    Hefei, Anhui 230071, China
  • Beijing Peking Union Medical College Hospital-Department of Rheumatology and Immunology ( Site 2001)
    Beijing, Beijing Municipality 100730, China
  • Gansu Provincial Hospital ( Site 2065)
    Lanzhou, Gansu 730000, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 2036)
    Guangzhou, Guangdong 510000, China
  • Southern Medical University Nanfang Hospital ( Site 2037)
    Guangzhou, Guangdong 510515, China
  • The Affiliated Hospital of Guizhou Medical University ( Site 2051)
    Guiyang, Guizhou 550004, China
  • The Second Afilliated Hospital of Hebei Medical University-Immunology And Rheumatology ( Site 2064)
    Shijiazhuang, Hebei 050000, China
  • The First Affiliated Hospital of Henan University of Science &Technology ( Site 2041)
    Luoyang, Henan 471003, China
  • Tongji Hospital Tongji Medical,Science & Technology ( Site 2042)
    Wuhan, Hubei 430000, China
  • The First Affiliated Hospital of Nanhua University ( Site 2061)
    Hengyang, Hunan 421001, China
  • The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Te ( Site 2006)
    Baotou, Inner Mongolia 014010, China
  • Affiliated Hospital of Nantong University ( Site 2027)
    Nantong, Jiangsu 226001, China
  • Pingxiang People's Hospital ( Site 2005)
    Pingxiang, Jiangxi 337055, China
  • Jilin Province People's Hospital ( Site 2033)
    Changchun, Jilin 130021, China
  • The First Affiliated Hospital of Xi'an Jiaotong University ( Site 2056)
    Xi'an, Shaanxi 710061, China
  • Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 2053)
    Shanghai, Shanghai Municipality 200001, China
  • Shanxi Bethune Hospital ( Site 2029)
    Taiyuan, Shanxi 030032, China
  • The First Affiliated Hospital Of Chengdu Medical College ( Site 2052)
    Chengdu, Sichuan 610500, China
  • Tianjin Medical University General Hospital-Rheumatism and Immunology ( Site 2011)
    Tianjin, Tianjin Municipality 300052, China
  • Salud SURA Industriales ( Site 0508)
    Medellín, Antioquia 50021, Colombia
  • Centro Integral de Reumatología del Caribe ( Site 0501)
    Barranquilla, Atlántico 080002, Colombia
  • Clinica de la Costa S.A.S. ( Site 0502)
    Barranquilla, Atlántico 080020, Colombia
  • Preventive Care ( Site 0507)
    Chía, Cundinamarca 250001, Colombia
  • Healthy Medical Center S.A.S ( Site 0505)
    Zipaquirá, Cundinamarca 250252, Colombia
  • Fundación Valle del Lili ( Site 0506)
    Cali, Valle del Cauca Department 760032, Colombia
  • Centro de Estudios de Reumatología y Dermatología SAS ( Site 0512)
    Cali, Valle del Cauca Department 760042, Colombia
  • CHU Bordeaux Haut-Leveque ( Site 1007)
    Pessac, Aquitaine 33600, France
  • Centre Hospitalier Saint Joseph - Saint Luc ( Site 1003)
    Lyon, Auvergne-Rhône-Alpes 69007, France
  • CHU Rangueil ( Site 1008)
    Toulouse, Haute-Garonne 31400, France
  • CHU Montpellier Lapeyronie Hospital-Rhumatologie ( Site 1006)
    Montpellier, Herault 34295, France
  • Hopital Claude Huriez - CHU de Lille ( Site 1005)
    Lille, Nord 59037, France
  • Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord ( Site 1009)
    Saint Priest En Jarez, Pays de la Loire Region 42270, France
  • Clínica Médica Especializada en Pediatría e Infectología Pediátrica - Dr. Mario Melgar ( Site 0602)
    Guatemala City, 01009, Guatemala
  • CELAN,S.A ( Site 0603)
    Guatemala City, 01010, Guatemala
  • Clinica Medica Especializada en Medicina Interna y Reumatología ( Site 0601)
    Guatemala City, 01010, Guatemala
  • Istituto Clinico Humanitas Research Hospital ( Site 1310)
    Rozzano, Milano 20089, Italy
  • Fondazione Policlinico Universitario Campus Bio-Medico ( Site 1307)
    Rome, Roma 00128, Italy
  • Azienda Ospedaliero Universitaria Senese-Medicina Interna e Specialistica ( Site 1306)
    Siena, Tuscany 53100, Italy
  • Azienda Ospedale - Università Padova-Department of Medicine-DIMED ( Site 1309)
    Padova, Veneto 35128, Italy
  • AOU Careggi ( Site 1311)
    Florence, 50141, Italy
  • Azienda Ospedaliera Universitaria dell'Università "Luigi Van-UNITA'OPERATIVA DI REUMATOLOGIA, DIPAR ( Site 1305)
    Naples, 80131, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -UOC Reumatologia ( Site 1304)
    Roma, 00168, Italy
  • Japan Community Healthcare Organization Chukyo Hospital ( Site 2107)
    Nagoya, Aichi-ken 457-8510, Japan
  • St. Marianna University Hospital ( Site 2121)
    Kawasaki, Kanagawa 216-8511, Japan
  • Tohoku University Hospital ( Site 2116)
    Sendai, Miyagi 980-8574, Japan
  • Yuuai Medical Center ( Site 2122)
    Tomigusuku, Okinawa 901-0224, Japan
  • Shimane University Hospital ( Site 2119)
    Izumo, Shimane 693-0021, Japan
  • Dokkyo Medical University Hospital ( Site 2118)
    Shimotsuga, Tochigi 321-0293, Japan
  • Nihon University Itabashi Hospital ( Site 2105)
    Itabashiku, Tokyo 173-8610, Japan
  • Showa Medical University East Hospital ( Site 2123)
    Shinagawa, Tokyo 142-0054, Japan
  • Chiba University Hospital ( Site 2120)
    Chiba, 260-8677, Japan
  • NHO Chiba Medical Center Chibahigashi National Hospital ( Site 2112)
    Chiba, 260-8712, Japan
  • Okayama University Hospital ( Site 2106)
    Okayama, 700-8558, Japan
  • Osaka Keisatsu Hospital ( Site 2117)
    Osaka, 543-8922, Japan
  • Hospital Canselor Tuanku Muhriz UKM ( Site 2225)
    Cheras, Kuala Lumpur 56000, Malaysia
  • University Malaya Medical Centre-Clinical Investigation Centre (CIC) ( Site 2222)
    Lembah Pantai, Kuala Lumpur 59100, Malaysia
  • Hospital Tengku Ampuan Afzan-Medical Outpatient Department ( Site 2224)
    Kuantan, Pahang 25100, Malaysia
  • Hospital Taiping ( Site 2221)
    Taiping, Perak 34000, Malaysia
  • Morales Vargas Centro de Investigacion ( Site 0710)
    León, Guanajuato 37000, Mexico
  • Centro Integral en Reumatologia ( Site 0701)
    Guadalajara, Jalisco 44160, Mexico
  • Centro de Atención en Enfermedades Inflamatorias CATEI ( Site 0707)
    Guadalajara, Jalisco 44638, Mexico
  • Clinica de Investigacion en Reumatologia y Obesidad S. C. ( Site 0705)
    Guadalajara, Jalisco 44650, Mexico
  • Centro de Estudios de Investigacion Basica y Clinica ( Site 0708)
    Guadalajara, Jalisco 44690, Mexico

Showing the first 100 of 127 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Jul 2025, 19 months.

Results were first posted in Aug 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Dec 7, 2023
StartActual
Dec 27, 2023
Primary completionActual
Jul 30, 2025
CompletionActual
Jul 30, 2025
Results first posted
Aug 10, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06161116
Responsible party
Sponsor
First posted
Dec 7, 2023
Start date
Dec 27, 2023
Primary completion
Jul 30, 2025
Completion
Jul 30, 2025
Results posted
Aug 10, 2026
Last update
Aug 10, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-6194

Start the discussion